News

Video

Dr Bazhenova on Potential Combination Strategies With KRAS G12C Inhibitors in Advanced NSCLC

Author(s):

Lyudmila A. Bazhenova, MD
Conference|International Lung Cancer Congress

Lyudmila A. Bazhenova, MD, discusses potential combination strategies with KRAS G12C inhibitors in advanced non–small cell lung cancer.

Lyudmila A. Bazhenova, MD, medical oncologist, professor of clinical medicine, University of California San Diego Moores Cancer Center, discusses potential combination strategies with KRAS G12C inhibitors in KRAS G12C–mutant advanced non–small cell lung cancer.

Related Videos
VK Gadi, MD, PhD
Komal Jhaveri, MD, FACP
Mark Pegram, MD
David R. Spigel, MD, chief scientific officer, Sarah Cannon Research Institute
Rene Adam, MD, PhD
Timothy Hughes, MD, MBBS, FRACP, FRCPA
Mikkael A. Sekeres, MD, professor, medicine, chief, Division of Hematology, Leukemia Section, the University of Miami Sylvester Comprehensive Cancer Center
Hetty E. Carraway, MD, MBA
Tycel Phillips, MD, MPH
Mazyar Shadman, MD, MPH
Related Content
Sundar Jagannath, MBBS, director, the Center of Excellence for Multiple Myeloma, professor, Medicine, Mount Sinai Tisch Cancer Institute
June 7th 2024

Linvoseltamab Generates Efficacy Similar to That Seen With Teclistamab in R/R Myeloma

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

Fernando Cotait Maluf, MD
June 7th 2024

Pembrolizumab With Platinum-Based Therapy is Safe and Efficacious in PSCC

Hari B. Keshava, MD
October 23rd 2023

Keshava Emphasizes the Importance of Lung Nodule Programs for Early Lung Cancer Detection

Roger Li, MD
June 6th 2024

High CR Rate in NMIBC Is Maintained by Cretostimogene Grenadenorepvec Plus Pembrolizumab

Ronald C. Chen, MD, MPH, FASCO, FASTRO
June 6th 2024

Intensification With Apalutamide/ADT Improves PSA PFS in Biochemically Recurrent Prostate Cancer